Cargando…
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory protein alpha (SIRPα) on a macrophage and CD47 on all types of cells – ranging from blood cells to cancer cells. This interaction has emerged over the last decade as a potential co-target in cancer when combined wi...
Autores principales: | Jalil, AbdelAziz R, Andrechak, Jason C, Discher, Dennis E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206415/ https://www.ncbi.nlm.nih.gov/pubmed/32421049 http://dx.doi.org/10.1093/abt/tbaa006 |
Ejemplares similares
-
CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
por: Andrechak, Jason C., et al.
Publicado: (2022) -
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2022) -
Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)